



WELCURE DRUGS & PHARMACEUTICALS LTD.

CIN: L24232DL1996PLC227773

Regd. Off.: Plot No. 55, Office No- 104 First Floor Vijay Block , Laxmi Nagar, East Delhi, Delhi-110092

Email: welcuredrugs227@gmail.com Website: www.welcuredrugs.com

Date-14th November, 2024

To,
The General Manager,
Corporate Relationship Department,
BSE Limited,
Phiroz Jeejeebhoy Tower,
Dalal Street, Mumbai — 400001,
Maharashtra, India

Reference : ISIN - INE331C01017 Scrip Code-524661; Symbol- WELCURE

Subject: Outcome of the Meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Limited held on today i.e. Thursday, 14th November, 2024.

Dear Sir/Madam,

Pursuant to the Regulation 30 and other applicable regulations of the SEBI (Listing obligation & Disclosure requirements) Regulations, 2015 and in continuation of our earlier Intimation of the Board Meeting dated 07th, November 2024 we hereby inform you that meeting of the Board of Directors of the Company, duly convened and held at the registered office of the Company i.e Plot No. 55, Office No- 104 First Floor Vijay Block, Laxmi Nagar, East Delhi, Delhi-110092, on Thursday, November 14, 2024 at 02:00 P.M. (i.e., 1400 Hours) and concluded at 3.15 P.M (i.e., 1515 Hours) the Board of Directors has inter alia transacted the following businesses:

1. The Board considered and approved the Unaudited Financial Results of the Company along with the Limited Review Report as issued by Statutory Auditor of the Company for the 2nd quarter and Half Year ended on 30th September 2024.

You are requested to please take the same in your record.

Thanking you,
Yours truly,

FOR WELCURE DRUGS & PHARMACEUTICALS LTD.

Altat Hussain Shah
Digitally signed by
Altat Hussain Shah
Date: 2024.11.14
15:16:44 +05'30'

**ALTAF HUSSAIN SHAH
MANAGING DIRECTOR AND CFO
DIN- 10351528**



Independent Auditor's Limited Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors of
WELCURE DRUGS & PHARMACEUTICALS LIMITED

1. We have reviewed the accompanying statement of unaudited financial results (The "Statement") of WELCURE DRUGS & PHARMACEUTICALS LIMITED ("the Company") for the quarter ended September 30, 2024 and year to date from April 01, 2024 to September 30, 2024 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations")

Management's responsibility

2. The statement which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

Auditors' responsibility

3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of Material misstatement. A review is limited primarily to inquiry of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Basis for Disclaimer on Conclusion

4. The Audit of the Financial statements of the company for the quarter ended 30th September, 2024 could not be concluded as we were unable to obtain access to the relevant financial information so as to verify certain material transactions undertaken by the company

Disclaimer on Conclusion

5. Based on our review, except for the possible effects of the matter described in the Basis for Qualified Conclusion paragraph, we are unable to conclude that the accompanying statement

-
- H.O. : Office No. 16B, Khatau Building, 1st Floor, 8/10 Alkesh Dinesh Modi Marg, (Shahid Bhagat Singh Road), Fort, Mumbai - 400 023
Phone No : +91 22 4002 2072 / 4004 6887
 - Branch : 620, Goldcrest Business Park, Behind HDFC Bank, Near Shreyas, L.B.S. Road, Ghatkopar (W), Mumbai - 400 086
Phone No : +91 22 4973 3968 / 4973 4015

of unaudited financial results prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Gupta Rustagi & Co.**

Chartered Accountants

ICAI FRN : 128701W

NIRAJ

SUBHASHCHA

ND GUPTA

Digitally signed by NIRAJ
SUBHASHCHAND GUPTA
Date: 2024.11.14 13:49:53
+05'30'

Niraj Gupta

Partner

M.N.no. 100808

Place: Mumbai


Date: 14th November, 2024


UDIN: 24100808BKDICG9485

STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30/09/2024

Particulars	[RUPEES IN MILLIONS]					
	Three Months Ended on 30.09.2024	Three Months Ended on 30.06.2024	Three Months Ended on 30.09.2023	Half Year Ended on 30.09.2024	Half Year Ended on 30.09.2023	Year ended on 31.03.2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Revenue from operations	245.500	-	-	245.500	-	-
2. Other Income	0.000	-	0.024	0.000	0.024	0.939
3. Total Revenue (1+2)	245.500	-	0.024	245.500	0.024	0.939
4. Expenses	-	-	-	-	-	-
Cost of Materials consumed	-	-	-	-	-	-
Purchase of stock-in-trade	1,640.270	-	-	1,640.270	-	-
Change in inventories of Finished Goods, Work-in-Process and Stock-in-Trade	(1,435.236)	-	-	(1,435.236)	-	-
Employees benefits expenses	0.970	0.528	0.135	1.497	0.270	0.875
Finance Cost	-	-	-	-	-	-
Depreciation and Amortisation expense	0.056	0.020	0.100	0.076	0.100	0.359
Other Expenses	21.058	2.900	0.739	23.958	0.936	1.453
Total Expenses	227.117	3.448	0.974	230.565	1.306	2.687
5. Profit before exceptional and extraordinary items and tax (3 - 4)	18.383	(3.448)	(0.950)	14.935	(1.292)	(1.748)
6. Exceptional Items	-	-	-	-	-	-
7. Profit before extraordinary items and tax (5 - 6)	18.383	(3.448)	(0.950)	14.935	(1.292)	(1.748)
8. Extraordinary items	-	-	-	-	-	-
9. Profit before tax (7- 8)	18.383	(3.448)	(0.950)	14.935	(1.292)	(1.748)
10. Tax Expenses	-	-	-	-	-	-
11. Profit/(Loss) for the period from continuing operations (9 - 10)	18.383	(3.448)	(0.950)	14.935	(1.292)	(1.748)
12. Profit/(Loss) from discontinuing operations	-	-	-	-	-	-
13. Tax expense of discontinuing operations	-	-	-	-	-	-
14. Profit/(Loss) from Discontinuing operations (after tax) (12-13)	-	-	-	-	-	-
15. Profit/(Loss) for the period (11 + 14)	18.383	(3.448)	(0.950)	14.935	(1.292)	(1.748)
16. Other comprehensive income net of taxes	-	-	-	-	-	-
17. Total comprehensive income for the period (15+16)	18.383	(3.448)	(0.950)	14.935	(1.292)	(1.748)
18. Paid-up equity share capital(Face Value of Rs.10/-Per Share)	1,124.391	134.391	134.391	1,124.391	134.391	134.391
19.i Earing Per Share(EPS) (before extraordinary items) (Of Rs. 10/- each) (Not annualised except last column)						
(a) Basic	0.163	(0.257)	(0.071)	0.133	(0.096)	(0.130)
(b) Diluted	0.163	(0.257)	(0.071)	0.133	(0.096)	(0.130)
ii Earing Per Share(EPS) (after extraordinary items) (Of Rs. 10/- each) (Not annualised except last column)						
(a) Basic	0.163	(0.257)	(0.071)	0.133	(0.096)	(0.130)
(b) Diluted	0.163	(0.257)	(0.071)	0.133	(0.096)	(0.130)

For and on behalf of the Board of Directors


 Altaf Shah
 Director
 DIN: 10351528


 Suraj Solanki
 Director
 DIN: 10380845



Welcure Drugs & Pharmaceuticals Limited
Standalone Balance Sheet as at 30th September, 2024

(Rs. In Millions)

Particulars	For the Year Ended 30 September, 2024	For the Year Ended 31 March, 2024
ASSETS		
NON-CURRENT ASSETS		
(a) Property, plant and equipment	0.30	0.21
Capital work-in-progress	0.00	0.00
(b) Financial assets	0.00	0.00
(i) Investments	0.00	0.00
(ii) Loans	12.87	12.87
(c) Other non current assets	1.01	0.31
Total Non- Current Assets	14.19	13.39
CURRENT ASSETS	0.00	0.00
(a) Inventories	1435.24	0.00
(b) Financial assets	0.00	0.00
(i) Trade receivables	331.74	0.00
(ii) Cash and cash equivalents	2.27	0.22
(c) Other current assets	914.97	0.10
Total Current Assets	2684.22	0.32
TOTAL ASSETS	2698.40	13.71
EQUITY AND LIABILITIES	0.00	0.00
EQUITY	0.00	0.00
(a) Equity share capital	1124.39	134.39
(b) Other equity	-106.05	-120.99
	1018.34	13.40
LIABILITIES	0.00	0.00
NON-CURRENT LIABILITIES	0.00	0.00
(a) Financial liabilities	0.00	0.00
(i) Borrowings	0.00	0.00
(ii) Trade payables	0.00	0.00
(A) total outstanding dues of micro enterprises and small enterprises; and (B) total outstanding dues of creditors other than micro enterprises and small enterprises.	0.00	0.00
(iii) Other financial liabilities	0.00	0.00
(b) Provisions	0.00	0.00
(c) Non Current tax liabilities	0.00	0.00
(d) Deferred tax liabilities (net)	0.00	0.00
Total Non- Current Liabilities	0.00	0.00
CURRENT LIABILITIES	0.00	0.00
(a) Financial liabilities	0.00	0.00
(i) Borrowings	0.00	0.00
(ii) Trade payables	0.00	0.00
(A) total outstanding dues of micro enterprises and small enterprises; and (B) total outstanding dues of creditors other than micro enterprises and small enterprises.	1578.04	0.00
(iii) Other Financial liabilities	0.11	0.11
(b) Provisions	0.00	0.09
(c) Other Current liabilities	101.91	0.11
Total Current Liabilities	1680.06	0.31
TOTAL EQUITY AND LIABILITIES	2698.40	13.71

For and on behalf of the Board of Directors


Altaf Shah
Director

DIN: 10351528


Suraj Solanki
Director

DIN: 10380845



Welcure Drugs & Pharmaceuticals Limited
Cash Flow Statement for the Year Ended 30th September, 2024

Particulars		For the Year Ended 30 September, 2024	For the Year Ended 31 March, 2024
(A)	Cash flow from operating activities		
	Profit/(loss) before tax	14.94	(1.748)
	Adjusted for :	0.00	
	Depreciation and amortisation expense	0.08	0.359
	Interest income	0.00	-
	Finance cost	0.00	-
	Employee benefit expense	0.00	-
		15.01	(1.389)
	Operating profit/(loss) before working capital changes	0.00	
	Adjusted for :	0.00	
	(Increase)/Decrease in trade receivables	-331.74	-
	(Increase)/Decrease in inventories	-1435.24	-
	(Increase)/Decrease in financial & non financial assets	0.00	(0.056)
	(Increase)/Decrease in other assets- current	-914.87	-
	Increase/(Decrease) in trade payables	1578.04	-
	Increase/(Decrease) in other non current liabilities	0.00	-
	(Increase)/Decrease in financial & non financial Liabilities	101.80	0.170
	(Increase)/Decrease in Other financial Liabilities non current	0.00	-
	Increase/(Decrease) in provisions - Non Current	0.00	-
	Increase/(Decrease) in provisions	-0.09	-
		-1002.09	0.114
	Cash generated from operations	-987.08	(1.275)
	Net Income taxes (paid) / refunds	0.00	
	Net cash from operating activities	-987.08	(1.275)
		0.00	
(B)	Cash flow from investing activities	0.00	
	Capital expenditure on property, plant and equipment including capital advances	-0.17	-
	Purchases of investments	0.00	-
	(Increase)/Decrease in other non current assets	-0.70	
	Investments redeemed	0.00	1.650
	Net cash used in investing activities	-0.87	1.650
		0.00	
(C)	Cash flow from financing activities	0.00	
	Right Issue of shares	990.00	
	Amount received on Share Warrant	0.00	-
	(Repayment)/Proceeds from long-term borrowings	0.00	-
	(Repayment)/Proceeds from short term borrowings	0.00	-
	Loans given	0.00	(0.171)
	Dividends paid to company's shareholders	0.00	-
	Interest and finance charges paid	0.00	-
	Net cash used in financing activities	990.00	(0.171)
		0.00	
	Net (decrease) / increase in cash and cash equivalents	2.05	0.204
	Cash and cash equivalents as at the beginning of the year	0.22	0.012
	Cash and cash equivalents as at the end of the year	2.27	0.216

For and on behalf of the Board of Directors


Altaf Shah

Director
DIN: 10351528


Suraj Solanki

Director
DIN: 10380845

